This word means: Sundays on Cycle
Sunday (June 1) marked the 25th edition of the Fit India Sundays on Cycle initiative, which was dedicated as a tribute to India's armed forces under the banner of the 'Tiranga Rally' in multiple cities.
Over 1,200 cyclists participated in the rally at Major Dhyan Chand National Stadium in New Delhi, led by Union Minister for Youth Affairs and Sports Mansukh Mandaviya.
Fit India Sundays on Cycle is a nationwide fitness initiative to combat obesity. Launched in 2024 by the Ministry of Youth Affairs and Sports, the campaign aims to promote cycling as a sustainable, inclusive, and eco-friendly form of exercise.
As normal physical movement becomes limited and the dependency on food and grocery delivery apps increases for a section of the urban population, getting regular exercise has become a challenge. Cycling comes in here as a budget-friendly, high-impact form of exercise that not only improves cardiovascular health and boosts mental well-being but also addresses the risks of youth obesity.
Since its launch, the initiative has been held at over 5,000 locations, with participation from more than 3 lakh people. One can participate through a simple registration process on the MyBharat and Fit India website and mobile app.
Several Sports Authority of India (SAI) centres and Khelo India Centres (KICs) now host a variety of fitness activities during Sundays on Cycle events. These include Zumba, rope skipping, guided yoga sessions, and free health check-ups conducted by experts from the National Centre of Sports Sciences and Research (NCSSR).
Prime Minister Narendra Modi, in a recent Mann Ki Baat address, emphasised the need for nationwide awareness and collective action to reduce obesity, particularly through reducing edible oil consumption.
India is grappling with a silent yet serious health crisis. Once seen as an issue limited to urban lifestyles (although still concentrated there), obesity has now spread across all sections of society, cutting across age groups, genders, and income levels.
According to the World Health Organisation (WHO), obesity is a chronic complex disease defined by excessive fat deposits that can impair health. On the other hand, being overweight is a condition of excessive fat deposits.
The latest National Family Health Survey (NFHS-5, 2019–21) stated that over 24 per cent of Indian women and 23 per cent of Indian men are obese. Of greater concern is the rising number of children under the age of five who are now classified as overweight. A Lancet study earlier this year found that in 2021, India had overtaken China to become the country with the largest number of overweight and obese older adolescents, aged between 15 and 24.
This growing trend is largely driven by unhealthy eating habits, sedentary routines, and a sharp decline in physical activity — all increasingly common in modern Indian lifestyles. High levels of sugar, salt and food items are a matter of concern, especially as the MNCs producing them have shifted from high-income to low- and middle-income countries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
10 minutes ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'
NDTV
13 minutes ago
- NDTV
Idli vs Moong Chilla: Which Breakfast Actually Helps With Weight Loss
When you are trying to lose weight, even everyday decisions like what to eat for breakfast can feel unnecessarily complicated. You want something that is filling but not calorie-heavy. Something that tastes good but is also healthy. And most importantly, a breakfast that does not leave you hungry an hour later. The good news is that Indian breakfasts come with plenty of comforting options, but some dishes work better than others when weight loss is your priority. Two popular contenders in this space are idlis and moong chillas. Both sound healthy, but which one actually supports your weight goals better? If you often find yourself torn between the two, here is what you should know before your next breakfast. Also Read: 11 Desi Recipes To Try For Weight Loss Diet - For Breakfast, Lunch And Dinner Nutrition Comparison: Idli vs Moong Chilla One plain idli contains around 35 to 40 calories. It is low in fat and easy to digest, but primarily consists of carbohydrates since it is made using rice and urad dal. In contrast, a single moong chilla has around 120 to 130 calories. While that may sound like more, it also offers protein and dietary fibre, which help you stay full for longer. For those focusing on weight loss, moong chilla is a better pick. The protein helps control hunger, and the fibre slows digestion, both of which play key roles in managing cravings. Idlis are not a bad choice either, but they might not be as satisfying unless paired with something substantial like sambar. Which Keeps You Full Longer? If your goal is to stay full until lunch, moong chilla has the upper hand. According to Nutritionist Rashi Chowdhary, dals and dal-based batters take longer to digest, which means fewer mid-morning hunger pangs. The high protein and fibre in moong chilla also help regulate blood sugar levels, preventing sudden spikes and crashes that often trigger snacking. Idlis, though light and easy on the stomach, have a high glycaemic index and digest more quickly. So, if you eat them alone without a side like sambar, you might be rummaging through your snack drawer sooner than expected. Gut Health: Which Is Easier On The Stomach? This is where idlis come out ahead. Thanks to the fermentation process, idlis contain beneficial bacteria that support gut health and aid digestion. Their soft, fluffy texture also makes them gentle on the stomach, particularly helpful for those recovering from acidity or sensitive digestion. They are also less likely to cause bloating. On the other hand, moong chilla can sometimes lead to discomfort if your gut is not used to lentils, especially if the dal has not been soaked properly. Nutritionist Rashi Chowdhary advises soaking dals for at least four to six hours to soften their outer layer and ease digestion. Soaking not only keeps the nutrients intact but also reduces gas and bloating. That said, if lentils are a regular part of your diet, moong chilla should not cause any trouble. Weight Loss Verdict: Idli or Moong Chilla? If your main goal is managing weight and reducing cravings, moong chilla is the stronger option. It has higher amounts of protein and fibre, which help with satiety, making it a solid choice for anyone following a calorie-controlled diet. You can also boost its nutritional profile by pairing it with curd or mint chutney. That said, idlis are not off the table either. When made with ragi or oats and eaten with sambar, they become a light and gut-friendly meal. The key is to alternate between the two based on your energy needs and what your body feels like on a given day. It ultimately depends on your fitness goals and schedule. Also Read: 10 Mistakes To Avoid When You Are On Weight Loss Diet Tips To Make Your Moong Chilla Healthier 1. Add Vegetables To The Batter Moong chillas are typically plain, but you can enrich them with vegetables like grated carrots, spinach, cabbage, or capsicum. This adds fibre and micronutrients without increasing the calorie count. 2. Cook With Minimal Fat Use a cast-iron or non-stick pan, and brush it lightly with ghee. Avoid using too much oil; a small amount is enough to cook it through. 3. Pair It With Protein-Rich Curd Adding a bowl of curd on the side can balance the meal and promote digestion, thanks to the probiotics in curd. 4. Skip The Paneer Stuffing While paneer is a good protein source, it also increases the calorie count significantly. If weight loss is your goal, avoid adding paneer to your chilla. 5. Choose Whole Green Moong Whole green moong has more fibre compared to yellow moong dal. It takes slightly longer to soak but will keep you full for longer and adds a nutty depth of flavour. Disclaimer: This content including advice provides generic information only. It is in no way a substitute for qualified medical opinion. Always consult a specialist or your doctor for more information. NDTV does not claim responsibility for this information. Advertisement About Nikita Nikhil Meet Nikita, a passionate soul with an insatiable love for two things in life: Bollywood and food! When she's not indulging in binge-watching sessions, Nikita can be found behind the lens capturing moments or expressing her creativity through painting. For the latest food news, health tips and recipes, like us on Facebook or follow us on Twitter and YouTube. Tags: Idli Moong Chilla Weight Loss Breakfast Show full article
United News of India
40 minutes ago
- United News of India
Aster DM Healthcare to Invest Rs 580 cr in new hospital
Bengaluru, Aug 5 (UNI) Aster DM Healthcare today announced plans to set up its fifth multi-specialty hospital in Bengaluru with an investment of ₹580 crore. The new 500-bedded facility will be located in Yeshwanthpur, taking the total bed capacity of Aster hospitals in the city to 2,580. The new hospital will be built under a Built-to-Suit (BTS) model, consistent with Aster's asset-light expansion strategy. The facility is expected to be operational in the second half of FY 2028–29. The company has entered into a long-term lease agreement with Kemwell Pvt Ltd for 30 years, with provision for renewal. Speaking on the occasion, Dr Azad Moopen, Founder and Chairman of Aster DM Healthcare, said, 'The Yeshwanthpur hospital marks a major milestone in our India growth journey. With this addition, we are poised to become one of the top three healthcare providers in Bengaluru.' The planned facility, with a built-up area of 5 lakh sq ft, will be fully operated and managed by Aster. The group had recently announced a similar model-based hospital on Sarjapur Road. The hospital's location in Yeshwanthpur, a growing urban corridor in northwest Bengaluru, offers connectivity via Tumkur Road, Outer Ring Road, Bellary Road, and the Green Line of Namma Metro, in addition to its proximity to Yeshwanthpur Railway Junction. It will cater to a catchment population of 3–4 million people, including tech parks, industrial areas, and residential hubs. Aster DM Healthcare currently operates 19 hospitals with over 5,000 beds, along with 10 clinics, 203 pharmacies, and 259 labs and patient experience centers across five Indian states. UNI BDN GNK
